BoD & SCAP LOGIN

Prof. Paul J. Harrison, M.A., B.M., B.Ch., D.M. (Oxon), F.R.C.Psych.

  • Professor of Psychiatry and Associate Head of Department (Research), University of Oxford,
  • Honorary Consultant in General Adult Psychiatry, Oxford Health NHS Foundation Trust, 
  • Chair, Oxford Neuroscience Committee 


I trained in medicine and psychiatry in Oxford and London, and was a Wellcome Trust Senior Research Fellow before being appointed to my present post in 1997. I was awarded a Chair in 2000. I head a research group investigating molecular, psychopharmacological and therapeutic aspects of mood disorders and schizophrenia – and now the psychiatric and neurological aspects of COVID-19. I have published over 340 papers (Scopus h=77), and several books, including Shorter Oxford Textbook of Psychiatry, and Schizophrenia (with Daniel Weinberger). I am a Theme Leader in the NIHR Oxford Health Biomedical Research Centre, and an investigator in the Wellcome Centre for Integrative Neuroimaging. My clinical work centres on mood disorders, and includes recruitment to and running of clinical trials. I am a Deputy Editor for Biological Psychiatry. I have served on various funding committees, chaired an NHS Research Ethics Committee, and was Treasurer for the Academic Faculty of the Royal College of Psychiatrists. I have supervised 24 PhDs. Awards include the CINP/Paul Janssen Schizophrenia Prize (1998), the British Association for Psychopharmacology Senior Clinical Prize (1999), the A.E. Bennett Award of the Society of Biological Psychiatry (2004), the Joel Elkes Research Award of the American College of Neuropsychopharmacology (2005), the CINP Lilly Clinical Neuroscience award (2010), and the ECNP Clinical Neuropsychopharmacology award (2012). I was President of the British Association for Psychopharmacology from 2014-2016.

Selected publications

Colbourne CL, Harrison PJ (2022) Brain-penetrant calcium channel blockers are associated with a reduced incidence of neuropsychiatric disorders. Molecular Psychiatry (in press).

Taquet M, Dercon Q, Harrison PJ (2022) Six-month sequelae of post-vaccination SARS-CoV-2 infection: a retrospective cohort study of 10,124 breakthrough infections. Brain, Behaviour and Immunity 103 154-162.  doi.org/10.1016/j.bbi.2022.04.013.

De Picker L, Leboyer M, Geddes J, Morrens M, Harrison PJ, Taquet M (2022)  Association between serum lithium level and incidence of COVID-19 infection. British Journal of Psychiatry.  doi: 10.1192/bjp.2022.42

Hong J*/Atkinson LZ*, Al-Juffali N, Awad A, Geddes JR, Tunbridge EA, Harrison PJ*/Cipriani A* (2022) Gabapentin and pregabalin in bipolar disorder, anxiety states, and insomnia: systematic review, meta-analysis, and rationale. Molecular Psychiatry AOL 24.11.21.  doi.org/10.1038/s41380-021-01386-6   

Taquet M, Geddes JR, Luciano S, Harrison PJ (2022) Incidence and outcomes of eating disorders during the COVID-19 pandemic. British Journal of Psychiatry 220 262-264 doi.org/10.1192/bjp.2021.105

Taquet M, Harrison PJ (2022) Limiting the spread of COVID-19 or safeguarding mental health: a false dichotomy? Lancet Public Health   doi.org/10.1016/ S2468-2667(22)

Taquet M, Dercon Q, Husain M, Geddes JR, Luciano S, Harrison PJ (2021) Incidence, co-occurrence, and evolution of long-COVID features: a six-month retrospective cohort study of 273 618 survivors of COVID-19. PLoS Medicine 18: e1003773 (pp. 23). doi.org/10/10371/journal.pmed.1003773.

Taquet M, Husain M, Geddes JR, Luciano S, Harrison PJ (2021) Cerebral venous thrombosis and portal vein thrombosis: a retrospective cohort study of 537,913 COVID-19 cases. EClinicalMedicine 39 101061 (pp. 6). 

Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ (2021) 6-month neurological and psychiatric outcomes in 236 379 surviviors of COVID-19: a retrospective cohort study. Lancet Psychiatry 8 416-427.

Harrison PJ, Colbourne L, Luciano S  (2021)  Incidence of neurodegenerative and cerebrovascular diseases associated with anti-hypertensive drug classes. British Journal of Psychiatry  218 283-285.

de los Angeles A, Brennand KJ, Hall NA, Fernando M, Harrison PJ, Maher BJ, Weinberger DR, Tunbridge EM (2021) Induced pluripotent stem cells in psychiatry: an overview and critical perspective. Biological Psychiatry 90 362-372.

Harrison PJ, Hall N, Mould A, Al-Juffali N, Tunbridge EM (2021) Cellular calcium in bipolar disorder: systematic review and meta-analysis. Molecular Psychiatry 26 4106-4616.

Taquet M, Smith SM, Prohl A, Peters JM, Warfield S, Scherrer B/ Harrison PJ (2021) A structural brain network of vulnerability to psychiatric illness identified by genome-connectome covariation. Molecular Psychiatry 26 2089-2100.

Harrison PJ, Colbourne L, Harrison CH (2020) The neuropathology of bipolar disorder: systematic review and meta-analysis. Molecular Psychiatry 25 1787-1808.

Tunbridge EM, Narajos M, Harrison CH, Beresford C, Cipriani A, Harrison PJ. Which dopamine polymorphisms are functional? Systematic review and meta-analysis of  COMT, DAT, DBH, DDC, DRD1-DRD5, MAOA, MAOB, TH, VMAT1 and VMAT2. Biological Psychiatry  86 608-620.

Harrison PJ, Geddes JR, Tunbridge EM (2018) The emerging neurobiology of bipolar disorder. Trends in Neurosciences 41: 18-30.

Geddes J, Gardiner A, Rendell J…Goodwin G, Harrison PJ (2016) Comparative evaluation of quetiapine plus lamotrigine versus quetiapine monotherapy (and folic acid versus placebo) in bipolar depression: a randomized, double-blind, placebo-controlled trial (CEQUEL). Lancet Psychiatry 3: 31-39

Harrison PJ (2015) Recent genetic findings in schizophrenia and their therapeutic relevance. J Psychopharmacol 29: 85-96.

Cousijn H, Haegens S, Wallis G, Near J, Stokes M, Harrison PJ, Nobre AC (2014)  Resting GABA and glutamate concentrations do not predict visual gamma frequency or amplitude. PNAS 111: 9301-9306.

Law AJ, Wang Y, Sei Y, Harrison PJ, Kleinman J, Weinberger D (2012) NRG1-ErbB4-p110d signaling in schizophrenia and p110inhibition as a potential therapeutic strategy. PNAS  109: 12165-12170

Eastwood SL, Harrison PJ (2010) Markers of glutamate synaptic transmission and plasticity are increased in the anterior cingulate cortex in bipolar disorder. Biol Psychiatry 67: 1010-1016.  

Harrison PJ, Weinberger DR (2005) Schizophrenia genes, gene expression and neuropathology: on the matter of their convergence.  Molecular Psychiatry 10 40-68. PMID: 15263907.

Fairburn CG, Harrison PJ (2003) Eating disorders. Lancet 361 407-416. PMID:12573387.

Harrison PJ, Owen MJ (2003) Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet 361 417-419. PMID:12573388.

Geddes JR, Freemantle N, Harrison PJ, Bebbington P (2000) Atypical antipsychotics in the treatment of schizophrenia - systematic overview and meta-regression analysis. BMJ 321 1371-1376. PMID: 11099280.

Harrison PJ (1999) The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 122 593-624. PMID:10219775.

Harrison PJ, Eastwood SL (1998) Preferential involvement of excitatory neurons in medial temporal lobe in schizophrenia. Lancet 352 1669-1673. PMID:9853440.



Back